Key result
Higher triglyceride levels are linked to ~1% greater major cardiovascular events risk, varying by prior ACS.
Why the study?
Do triglyceride levels affect the risk of MACE and mortality differently in patients with a first versus recurrent ACS?
Cohort (n=14,483)
Yes
Do triglyceride levels affect the risk of MACE and mortality differently in patients with a first versus recurrent ACS?
Answers are grounded in this paper and cite their sources.
Previous ACS modifies the prognostic impact of triglyceride levels, with higher triglycerides associated with increased MACE risk in recurrent ACS and increased mortality risk in first ACS.
BACKGROUND: There is divergent evidence of triglycerides on cardiovascular prevention that might be explained by confounding factors. METHODS: We performed a multicenter and retrospective study using the ongoing registries of acute coronary syndrome (ACS) patients of 8 hospitals from Spain. Triglycerides were measured during the hospitalization, and mortality and major adverse cardiovascular events (MACE) were analysed through follow-up. RESULTS: We included 14,483 patients discharged after an ACS. Median triglycerides level was 120.5 (interquartile range [IQRS] 90-197) mg/dL and was slightly higher in patients with recurrent ACS (135 IQR 98-186 vs. 129 IQR 95-175; p < .01). Through the follow-up, 34.7% of the patients experienced a first MACE rate and 15.0% died. Multivariate analysis identified that triglycerides levels were associated with a higher risk of MACE (HR 1.01 95% CI 1.00-1.02, p = .021) but not with all-cause mortality (HR: 1.00 95% .99-1.02, p = .17). A significant interaction (p = .01) was observed for triglycerides and previous ACS for both endpoints and, therefore, analyses were performed separately. Triglycerides were only associated with a higher risk of MACE in patients with recurrent ACS (HR 1.03 95% CI 1.01-1.05, p = .012) and a higher risk of death in patients with a first ACS (HR 1.02 95% CI 1.01-1.04, p = .02). CONCLUSIONS: Previous ACS modifies the risk of triglycerides on MACE and mortality in patients discharged after an ACS. Triglycerides might be considered a target for treatment in patients after a first or recurrent ACS, although the expected benefit on outcomes might be different.
No takes yet. Share an insight, caveat, or question.
Cordero et al. (2025) conducted a cohort in acute coronary syndrome (n=14,483). Triglyceride levels was evaluated on major adverse cardiovascular events (MACE) (HR 1.01, 95% CI 1.00-1.02, p=0.021). Higher triglyceride levels were associated with an increased risk of major cardiovascular events, with the risk modified by whether the ACS was a first or recurrent event.
Synapse has enriched 10 related papers. Consider them for comparative context: